R
Rajiv Narayan
Researcher at Broad Institute
Publications - 39
Citations - 6113
Rajiv Narayan is an academic researcher from Broad Institute. The author has contributed to research in topics: Gene expression profiling & Auditory cortex. The author has an hindex of 22, co-authored 37 publications receiving 3885 citations. Previous affiliations of Rajiv Narayan include Boston University & Harvard University.
Papers
More filters
Journal ArticleDOI
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.
Aravind Subramanian,Rajiv Narayan,Steven M. Corsello,Steven M. Corsello,David Peck,Ted Natoli,Xiaodong Lu,Joshua Gould,John F. Davis,Andrew A. Tubelli,Jacob K. Asiedu,David L. Lahr,Jodi E. Hirschman,Zihan Liu,Melanie Donahue,Bina Julian,Mariya Khan,David Wadden,Ian Smith,Daniel D. Lam,Arthur Liberzon,Courtney Toder,Mukta Bagul,Marek Orzechowski,Oana M. Enache,Federica Piccioni,Sarah A. Johnson,Nicholas J. Lyons,Alice H. Berger,Alice H. Berger,Alykhan F. Shamji,Angela N. Brooks,Angela N. Brooks,Anita Vrcic,Corey Flynn,Jacqueline Rosains,David Y. Takeda,David Y. Takeda,Roger Hu,Desiree Davison,Justin Lamb,Kristin Ardlie,Larson Hogstrom,Peyton Greenside,Nathanael S. Gray,Nathanael S. Gray,Paul A. Clemons,Serena J. Silver,Xiaoyun Wu,Wen-Ning Zhao,Wen-Ning Zhao,Willis Read-Button,Xiaohua Wu,Stephen J. Haggarty,Stephen J. Haggarty,Lucienne Ronco,Jesse S. Boehm,Stuart L. Schreiber,Stuart L. Schreiber,Stuart L. Schreiber,John G. Doench,Joshua A. Bittker,David E. Root,Bang Wong,Todd R. Golub +64 more
TL;DR: The expanded CMap is reported, made possible by a new, low-cost, high-throughput reduced representation expression profiling method that is shown to be highly reproducible, comparable to RNA sequencing, and suitable for computational inference of the expression levels of 81% of non-measured transcripts.
Posted ContentDOI
A Next Generation Connectivity Map: L1000 Platform And The First 1,000,000 Profiles
Aravind Subramanian,Rajiv Narayan,Steven M. Corsello,David Peck,Ted Natoli,Xiaodong Lu,Joshua Gould,John F. Davis,Andrew A. Tubelli,Jacob K. Asiedu,David L. Lahr,Jodi E. Hirschman,Zihan Liu,Melanie Donahue,Bina Julian,Mariya Khan,David Wadden,Ian Smith,Daniel D. Lam,Arthur Liberzon,Courtney Toder,Mukta Bagul,Marek Orzechowski,Oana M. Enache,Federica Piccioni,Alice H. Berger,Alykhan F. Shamji,Angela N. Brooks,Anita Vrcic,Corey Flynn,Jacqueline Rosains,David Y. Takeda,Desiree Davison,Justin Lamb,Kristin Ardlie,Larson Hogstrom,Nathanael S. Gray,Paul A. Clemons,Serena J. Silver,Xiaoyun Wu,Wen-Ning Zhao,Willis Read-Button,Xiaohua Wu,Stephen J. Haggarty,Lucienne Ronco,Jesse S. Boehm,Stuart L. Schreiber,John G. Doench,Joshua A. Bittker,David E. Root,Bang Wong,Todd R. Golub +51 more
TL;DR: A new, low-cost, high throughput reduced representation expression profiling method, L1000, is shown to be highly reproducible, comparable to RNA sequencing, and suitable for computational inference of the expression levels of 81% of non-measured transcripts.
Journal ArticleDOI
The Drug Repurposing Hub: a next-generation drug library and information resource
Steven M. Corsello,Joshua A. Bittker,Zihan Liu,Joshua Gould,Patrick McCarren,Jodi E. Hirschman,Stephen Johnston,Anita Vrcic,Bang Wong,Mariya Khan,Jacob K. Asiedu,Rajiv Narayan,Christopher C. Mader,Aravind Subramanian,Todd R. Golub +14 more
TL;DR: This work hand-curated a collection of 4,707 compounds, experimentally confirmed their identities, and annotated them with literature-reported targets, to assemble a comprehensive library of drugs that have reached the clinic and established a blueprint for others to easily assemble such a repurposing library.
Journal ArticleDOI
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Cory M. Johannessen,Laura A. Johnson,Laura A. Johnson,Laura A. Johnson,Federica Piccioni,Aisha Townes,Dennie T. Frederick,Melanie Donahue,Rajiv Narayan,Keith T. Flaherty,Jennifer A. Wargo,David E. Root,Levi A. Garraway,Levi A. Garraway +13 more
TL;DR: Systematic gain-of-function resistance studies suggest that oncogenic dysregulation of a melanocyte lineage dependency can cause resistance to RAF–MEK–ERK inhibition, which may be overcome by combining signalling- and chromatin-directed therapeutics.
Journal ArticleDOI
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.
Steven M. Corsello,Steven M. Corsello,Rohith T. Nagari,Ryan Spangler,Jordan Rossen,Mustafa Kocak,Jordan Bryan,Jordan Bryan,Ranad Humeidi,David Peck,Xiaoyun Wu,Anna Tang,Vickie M. Wang,Sam Bender,Evan Lemire,Rajiv Narayan,Philip Montgomery,Uri Ben-David,Uri Ben-David,Colin W. Garvie,Yii-Der Ida Chen,Matthew G. Rees,Nicholas J. Lyons,James M. McFarland,Bang Wong,Li Wang,Nancy Dumont,Patrick O'Hearn,Eric Stefan,Eric Stefan,John G. Doench,Caitlin N. Harrington,Heidi Greulich,Matthew Meyerson,Matthew Meyerson,Francisca Vazquez,Ayshwarya Subramanian,Jennifer Roth,Joshua Bittker,Joshua Bittker,Jesse S. Boehm,Christopher C. Mader,Aviad Tsherniak,Todd R. Golub +43 more
TL;DR: An unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines in a manner predictable from the cell lines' molecular features.